Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SARS-CoV-2 Spike Glycoprotein (Delta Variant) (Spike (Delta))
- Target
- Spike (Delta)
- Molecular classification
- Glycoprotein, Viral protein, Fusion protein, Receptor Ligand
01
Overview
The SARS-CoV-2 spike glycoprotein is a large, trimeric, class I fusion protein that decorates the surface of the virus and mediates viral entry into host cells. The Delta variant (lineage B.1.617.2) features specific mutations in its spike protein—most notably L452R and T478K within the RBD—which increase binding affinity for ACE2 and contribute to higher infectivity. Unique among studied variants, Delta variant spikes promote aggregation of pseudotyped particles through spike-spike tip interactions. The spike glycoprotein is a primary target for neutralizing antibodies elicited by infection or vaccination, making it central both as a therapeutic target and vaccine antigen.
- Other names
- SARS-CoV-2 Delta Spike ProteinSpike protein (B.1.617.2)Delta SpikeB.1.617.2 spike glycoprotein
02
Mechanism of action
Binding to ACE2 receptor to mediate viral entry; targeted by neutralizing antibodies that block ACE2 interaction or fusion
03
Biological functions
Viral entryReceptor binding (ACE2)Membrane fusionImmune evasionVirion aggregation
04
Disease associations
InfectionCOVID-19Viral pathogenesis
05
Safety considerations
Antibody-dependent enhancement (ADE)Immune evasion (reduced vaccine efficacy)Potential for increased infectivity/transmissibilityRisk of mutations leading to new variants
06
Interacting drugs
Neutralizing antibodies (e.g., monoclonal antibodies)
2 more in the full profile.
07
Biomarkers
Spike protein antibody levels (vaccine efficacy)Viral load (Spike protein detection)ACE2 expression levelsPresence of specific mutations (L452R, T478K)
Beyond the preview
Go deeper on SARS-CoV-2 Spike Glycoprotein (Delta Variant) (Spike (Delta)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 Spike Glycoprotein (Delta Variant) (Spike (Delta)).